Fujirebio Europe introduces the new LUMIPULSE® G600II benchtop analyzer on the European market

Product news

Gent, Belgium: October 1st 2014 - The LUMIPULSE G600II, a new member in the LUMIPULSE G series of chemiluminescent enzyme immunoassay (CLEIA) analyzers from Fujirebio, is now available on the European market. The LUMIPULSE G600 II is a compact and robust benchtop analyzer which features a constant throughput of 60 tests per hour.

“The new LUMIPULSE G600 II uses the same unique mono cartridge concept as the LUMIPULSE G1200 and will allow us to offer our customers an already well-established routine menu of Lumipulse G tests completed by unique markers.” said Christiaan De Wilde, CEO of Fujirebio Europe. “This compact and easy-to-use benchtop system is a perfect fit in laboratories looking for personalized workflow solutions ranging from low assay volumes and onwards without compromising testing quality.”

Fujirebio has successfully been designing, manufacturing and marketing automated immunoassay testing solutions for more than 20 years. The mid-sized LUMIPULSE G1200 was first introduced in Europe in 2011. The new LUMIPULSE® G600II benchtop analyzer was made available in Japan for the first time earlier this year.

Shortcut to the product page:

This product is not available in the USA and in Canada.

About Fujirebio

Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.

The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone.

Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1.100 employees working in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english or www.fujirebio-europe.com.

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.